-
Two major pharmaceutical companies join hands to jointly carry out clinical trials of drugs under research for peritoneal cancer
Time of Update: 2021-12-29
The agreement stipulates that the two parties will jointly evaluate Shamrock Bio's recombinant human TRAIL-trimer fusion protein (SCB-313) and the SMAC mimic/inhibitor of apoptosis protein (IAP) targeted therapy small molecule antagonist ( APG-1387), the effect of combined treatment of advanced peritoneal cancer in phase 1b/2 clinical trials .
-
The medical device market has a bright future and is facing many challenges
Time of Update: 2021-12-29
In general, since this year, under the continuous promotion of policies, the medical device industry is accelerating its development .
-
Asia-Pacific Pharmaceuticals Receives Acceptance Notice for Consistency Evaluation of Terazosin Hydrochloride Tablets
Time of Update: 2021-12-29
On December 9, Asia-Pacific Pharmaceuticals issued an announcement stating that it had recently received an acceptance notice on the consistency evaluation of terazosin hydrochloride tablets issued by the National Medical Products Administration .
Oral administration of terazosin hydrochloride tablets is also suitable for the treatment of symptoms caused by benign prostatic hyperplasia (BPH) .
-
Implementation Rules for the Management of Chinese Medicine Formula Granules in Fujian Province Issued
Time of Update: 2021-12-29
(Chen Siyuan) A few days ago, the Fujian Provincial Food and Drug Administration, the Provincial Health Commission, and the Provincial Medical Insurance Bureau jointly issued the "Implementation Rules for the Management of Chinese Medicine Formula Granules in Fujian Province (Trial)" (hereinafter referred to as the "Detailed Rules") to further standardize and strengthen the management of Fujian Province Chinese Medicine Formula Granules .
-
CDE releases 2 technical guidelines for clinical trials involving weight control and advanced prostate cancer
Time of Update: 2021-12-29
Attachment: Notice on Technical Guidelines for Clinical Trials of Weight Control Drugs Regarding the Public Solicitation of "Technical Guidelines for Endpoints for Advanced Prostate Cancer Clinical Trials (Draft for Comment)" Prostate cancer is a common urinary system malignant tumor, which is unique compared to other solid tumors The characteristics of the disease, such as different disease stages according to the sensitivity to androgen deprivation treatment and whether it has metastasis, high incidence of bone metastasis and serum biomarker PSA, etc.
-
First-line treatment for nasopharyngeal cancer BeiGene PD-1 inhibitor combination significantly prolongs PFS in patients
Time of Update: 2021-12-29
On December 10, 2021, BeiGene announced that the anti-PD-1 antibody tislelizumab combined with chemotherapy, a phase 3 clinical trial for the first-line treatment of patients with recurrent/metastatic nasopharyngeal carcinoma reached the primary endpoint .
-
The State Food and Drug Administration held a seminar on the supervision of online sales of medical devices
Time of Update: 2021-12-29
On December 9, the State Food and Drug Administration held a medical device online sales supervision work exchange meeting to implement the "Medical Device Supervision and Administration Regulations"
-
At the end of the year, the personnel adjustment of multinational pharmaceutical companies has accelerated!
Time of Update: 2021-12-29
It is understood that after the release of the sixth batch of special insulin procurement results, the adjustment of personnel from many multinational pharmaceutical companies involved in the centralized procurement including Novo Nordisk and Sanofi has been accelerated .
-
Sino Medical's new class of drug-eluting stent system application for pre-market approval in the United States is accepted
Time of Update: 2021-12-29
On December 9, Sino Medical issued an announcement stating that in December 2021, it had submitted the final application for the company’s new type of healing-oriented drug-eluting stent system (trade name: HT Supreme) to the U.
The company’s new drug-eluting stent system was officially accepted by the FDA and entered the final pre-market approval (PMA) review process .
-
Jiangsu Wuzhong Trimetazidine Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate
Time of Update: 2021-12-29
In ischemic cells, lower oxygen consumption is required to obtain energy through glucose oxidation compared to the β-oxidation process .
Enhancing glucose oxidation can optimize the energy process of cells, thereby maintaining proper energy metabolism during ischemia .
-
Promoting the development of the pharmaceutical industry has become an important task for all regions
Time of Update: 2021-12-29
The industry believes that the release of this policy will continue to promote the development of innovative drugs in Daxing District and accelerate the technological innovation of the medical device industry, and undertake the achievements of Beijing and global scientific and technological innovations, continue to attract domestic and international high-quality resources, and achieve a high-quality cluster of the pharmaceutical and health industry in Daxing District Style development .
-
More than 30 pharmaceutical companies will be listed on the Sci-tech Innovation Board by 2021, and the market value of four will exceed 30 billion yuan
Time of Update: 2021-12-29
187 billion yuan Chengda Biologics was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on October 28, 2021, and its current new market value is 32.
-
In 2022, what are the new technological directions of the innovative drug track worth paying attention to?
Time of Update: 2021-12-29
Small nucleic acid drugs, or RNAi technology drugs, are currently the focus of research in the industry.
It is understood that the key technology for the development of small nucleic acid interference therapy mainly lies in delivery technology and RNAi molecular design.
-
Guotan medicines have started to apply online!
Time of Update: 2021-12-29
On December 3, the results of the 2021 national drug negotiations were finally "officially announced.
Newly added medicines in the medical insurance catalogueNew medical insurance negotiation drugs
-
In November, the amount of holdings in the pharmaceutical and biological industry exceeded 100 million yuan
Time of Update: 2021-12-29
Looking back at the increase in shares held by the directors, supervisors and senior executives of listed companies on the Shanghai and Shenzhen stock exchanges in November and their affiliates, the cumulative increase in holdings during the month was approximately 421 million yuan, involving 91 companies .
-
In the past week, more than 16 biomedical companies have been investigated by institutions!
Time of Update: 2021-12-29
According to statistics, in the past week (December 1st to December 7th), at least 16 biomedical companies have been investigated by institutions, including Corfu Medical, Jincheng Pharmaceutical, Robust Medical, Xianju Pharmaceutical, Jincheng Pharmaceutical, and Panlong Pharmaceuticals, Yuekang Pharmaceuticals, etc.
-
Group heroes compete to increase R&D investment, domestic innovative drugs will show a blowout trend
Time of Update: 2021-12-29
In recent years, pharmaceutical companies have placed more emphasis on innovative drugs, and with the continuous increase in R&D investment, the approval of domestically-made innovative drugs has also shown a blowout trend .
-
In rushing to the "last train" of 2021, the chairman of two pharmaceutical companies resigned!
Time of Update: 2021-12-29
Chairman of China Resources Sanjiu resigns On December 3, China Resources Sanjiu issued an announcement stating that the board of directors received a resignation report from Chairman Wang Chuncheng.
The current deputy general manager of China Resources Group and the chairman of the board of directors of China Resources Pharmaceutical Group Co.
-
Hengrui Medicine's PD-1 Inhibitor Carrelizumab Approved for New Indication
Time of Update: 2021-12-29
On December 10, China's National Food and Drug Administration (NMPA) recently announced that Hengrui Medicine's PD-1 inhibitor carrelizumab has been approved for the marketing of two new indications .
-
Two more senior executives of multinational pharmaceutical companies may switch to local companies
Time of Update: 2021-12-29
Eid, an expert in the medical field, officially announced that he had joined Hengrui Pharmaceuticals as executive vice president, chief medical officer and head of global drug development.
